Product Overview
The 5′ cap structure is essential for the stability and translation of eukaryotic mRNA. Hyasen Vaccinia Virus Capping Enzyme catalyzes the formation of a 5′ Cap 0 structure (m7GpppN) through its RNA triphosphatase, guanylyltransferase, and guanine methyltransferase activities. It is suitable for enzymatic capping of in vitro transcribed RNA and can be combined with mRNA Cap 2′-O-Methyltransferase for further conversion to Cap 1 RNA.
Components
| Components | 2KU | 10KU | 100KU | 1000KU |
| Vaccinia Virus Capping Enzyme (10 U/μL) | 0.2 mL | 1 mL | 10 mL | 100 mL |
| 10× Capping Buffer | 0.4 mL | 2×1mL | 2×10 mL | 2×100mL |
Product Features
- Post-IVT mRNA Capping: Supports enzymatic capping after RNA transcription.
- Three Enzymatic Activities: Combines RNA triphosphatase, guanylyltransferase, and guanine methyltransferase functions.
- Quality Controlled: Tested for residual RNase and DNA nuclease activities.
FAQ
Q1: What is Vaccinia Virus Capping Enzyme used for?
It is used to add a 5′ Cap 0 structure to RNA transcripts, supporting mRNA preparation for downstream translation-related applications.
Q2: Does Vaccinia Virus Capping Enzyme produce Cap 0 or Cap 1?
It produces Cap 0. An additional Cap 2′-O-Methyltransferase reaction is required to convert suitable Cap 0 RNA into Cap 1 RNA.
Q3: What are the recommended capping conditions?
Hyasen recommends incubation at 37°C for 30 minutes, using the supplied 10× Capping Buffer, GTP, and SAM.